Charles River Laboratories International, Inc. has launched its nAAVigation Vector Platform (nAAVigation), a platform which streamlines the pathway to GMP Adeno-Associated Virus (AAV) vector manufacturing without the need for significant process development. According to the company, the nAAVigation platform has the capability to reduce a program’s timeline to GMP for viral vector gene therapy developers by 55 percent, translating to fewer than eight months compared to traditional manufacturing ...